TY - JOUR
T1 - Vaginal dose-surface maps in cervical cancer brachytherapy
T2 - Methodology and preliminary results on correlation with morbidity
AU - Serban, Monica
AU - de Leeuw, Astrid A.C.
AU - Tanderup, Kari
AU - Jürgenliemk-Schulz, Ina M.
N1 - Funding Information:
This work was supported by a research grant, R101_A6854_14_S31, from the Danish Cancer Society.
Publisher Copyright:
© 2021 American Brachytherapy Society
PY - 2021/5/1
Y1 - 2021/5/1
N2 - PURPOSE: The purpose of the study was to develop a methodology for vaginal dose-surface maps (DSMs) in patients with cervix cancer and to investigate dose-surface histogram metrics as predictors for vaginal stenosis (St) and mucositis (Muc).METHODS AND MATERIALS: Thirty-one patients with locally advanced cervix cancer with no vaginal St/Muc (CTCAE-v3) G ≥ 2 at baseline were analyzed. Patients were divided in four morbidity groups: 15 with St/Muc G0/1, 6 with St G ≥ 2, 4 with St/Muc G ≥ 2, and 6 with Muc G ≥ 2. Patients received external beam radiotherapy and 4-fraction intracavitary/interstitial high-dose-rate brachytherapy using tandem and ovoids. DSMs were generated from inner/outer vaginal surfaces. DSMs of external beam radiotherapy and brachytherapy (Gy EQD2
3) were added based on a system of homologous points, to generate cumulative DSMs. Dose-surface histogram/dose-volume histogram parameters, location of high/intermediate-dose regions, rectovaginal reference point, vaginal lateral 5 mm point doses, and vagina/implant dimensions were investigated for St and Muc prediction. Average/difference DSMs and one-way analysis of variance were used to compare between groups.
RESULTS: Best predictors of stenosis were D
15-25cm2 and upper-vagina S
65-120Gy(%). Cutoffs of ∼90 Gy EQD2
3 for D
20cm2 and ∼80% for S
65Gy to top 3 cm inner vaginal surface suitably discriminated for stenosis. Spatial dose location on average/difference DSMs showed significantly higher doses (by > 20 Gy, p < 0.001) over longer parts of the dorsolateral vagina and higher rectovaginal reference point doses for any G ≥ 2 morbidity, over the whole circumference of the upper vagina for G ≥ 2 stenosis. Dose-volume histogram parameters were dependent on vaginal wall thickness. An increase of wall thickness from 2 to 4 mm resulted in an increase of D
2cm3 (D
4cm3) of 16% (32%).
CONCLUSIONS: A novel method was developed to generate vaginal DSMs and spatial-dose metrics. DSMs were found to correlate with vaginal stenosis. The findings of this study are promising and should be further validated on a larger patient cohort, treated with different applicators.
AB - PURPOSE: The purpose of the study was to develop a methodology for vaginal dose-surface maps (DSMs) in patients with cervix cancer and to investigate dose-surface histogram metrics as predictors for vaginal stenosis (St) and mucositis (Muc).METHODS AND MATERIALS: Thirty-one patients with locally advanced cervix cancer with no vaginal St/Muc (CTCAE-v3) G ≥ 2 at baseline were analyzed. Patients were divided in four morbidity groups: 15 with St/Muc G0/1, 6 with St G ≥ 2, 4 with St/Muc G ≥ 2, and 6 with Muc G ≥ 2. Patients received external beam radiotherapy and 4-fraction intracavitary/interstitial high-dose-rate brachytherapy using tandem and ovoids. DSMs were generated from inner/outer vaginal surfaces. DSMs of external beam radiotherapy and brachytherapy (Gy EQD2
3) were added based on a system of homologous points, to generate cumulative DSMs. Dose-surface histogram/dose-volume histogram parameters, location of high/intermediate-dose regions, rectovaginal reference point, vaginal lateral 5 mm point doses, and vagina/implant dimensions were investigated for St and Muc prediction. Average/difference DSMs and one-way analysis of variance were used to compare between groups.
RESULTS: Best predictors of stenosis were D
15-25cm2 and upper-vagina S
65-120Gy(%). Cutoffs of ∼90 Gy EQD2
3 for D
20cm2 and ∼80% for S
65Gy to top 3 cm inner vaginal surface suitably discriminated for stenosis. Spatial dose location on average/difference DSMs showed significantly higher doses (by > 20 Gy, p < 0.001) over longer parts of the dorsolateral vagina and higher rectovaginal reference point doses for any G ≥ 2 morbidity, over the whole circumference of the upper vagina for G ≥ 2 stenosis. Dose-volume histogram parameters were dependent on vaginal wall thickness. An increase of wall thickness from 2 to 4 mm resulted in an increase of D
2cm3 (D
4cm3) of 16% (32%).
CONCLUSIONS: A novel method was developed to generate vaginal DSMs and spatial-dose metrics. DSMs were found to correlate with vaginal stenosis. The findings of this study are promising and should be further validated on a larger patient cohort, treated with different applicators.
KW - Cervical cancer brachytherapy
KW - Dose-surface histograms
KW - Dose-surface maps
KW - Vagina morbidity
KW - Vaginal mucositis
KW - Vaginal stenosis
KW - Radiotherapy Dosage
KW - Constriction, Pathologic
KW - Humans
KW - Brachytherapy/methods
KW - Vagina
KW - Morbidity
KW - Uterine Cervical Neoplasms/radiotherapy
KW - Female
UR - http://www.scopus.com/inward/record.url?scp=85102634703&partnerID=8YFLogxK
U2 - 10.1016/j.brachy.2021.02.004
DO - 10.1016/j.brachy.2021.02.004
M3 - Article
C2 - 33741274
AN - SCOPUS:85102634703
SN - 1538-4721
VL - 20
SP - 565
EP - 575
JO - Brachytherapy
JF - Brachytherapy
IS - 3
ER -